The physiological functioning of the brain is not well-known in current day medicine and the pathologies of many neuropsychiatric disorders are still not yet fully understood. With our aging population and better life expectancies, it has become imperative to find better biomarkers for disease progression as well as receptor target engagements. In the last decade, these major advances in the field of molecular CNS imaging have been made available with tools such as functional magnetic resonance imaging (fMRI), magnetic resonance spectroscopy (MRS), single photon emission computed tomography (SPECT), and neuroreceptor-targeted positron emission tomography (PET). These tools have given researchers, pharmaceutical companies, and clinical physicians a better method of understanding CNS dysfunctions, and the ability to employ improved therapeutic agents. This review is intended to provide an update on brain imaging agents that are currently used in clinical and translational research toward treatment of CNS disorders. The review begins with amyloid and tau imaging, the former of which has at least three [(18)F] agents that have been recently approved and will soon be available for clinical use for specific indications in the USA and elsewhere. Other prevalent PET and SPECT neurotransmitter system agents, including those newly US FDA-approved imaging agents related to the dopaminergic system, are included. A review of both mature and potentially growing PET imaging agents, including those targeting serotonin and opiate receptor systems, is also provided.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40263-015-0237-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Imaging flow cytometry reveals the mechanism of equine arteritis virus entry and internalization.
Sci Rep
January 2025
Department of Pathology, Division of Microbiology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, 50-375, Wroclaw, Poland.
The process of viral entry into host cells is crucial for the establishment of infection and the determination of viral pathogenicity. A comprehensive understanding of entry pathways is fundamental for the development of novel therapeutic strategies. Standard techniques for investigating viral entry include confocal microscopy and flow cytometry, both of which provide complementary qualitative and quantitative data.
View Article and Find Full Text PDFNon-medicinal oral contrast in upper abdominal MRI for MR-guided radiotherapy: A scoping review.
Radiography (Lond)
January 2025
Radiotherapy, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, UK; Leeds Institute of Medical Research, University of Leeds, Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds, UK.
Introduction: Using non-medicinal oral contrast agents may aid safe delivery of magnetic resonance image-guided (MR-guided) radiotherapy by improving the ability to visualise and avoid excessive radiation dose to adjacent bowel/stomach. This scoping review aims to map the literature on non-medicinal oral contrasts used in upper-abdominal diagnostic or therapeutic magnetic resonance imaging (MRI) to find potential candidates for employing in MR-guided radiotherapy and identify gaps in knowledge for further study.
Methods: A scoping review of non-medicinal oral contrast used in upper-abdominal MRI research followed a pre-defined protocol based on Arksey and O'Malley's framework.
Metallic nanoparticles biodistribution for the study of lymphoma in animal models.
Methods Cell Biol
January 2025
T Cell Lymphoma Group, Josep Carreras Leukaemia Research Institute, Barcelona, Spain. Electronic address:
T cell lymphoma constitutes a complex group of diseases, characterized by heterogeneous molecular features and clinical symptoms, and a dismal outcome no matter the therapeutic strategy chosen. In an attempt to improve patients' survival chances, treatment combinations (chemotherapy, radiotherapy, immunotherapy, gene therapy and thermotherapy) have been tested for their synergistic effects that may dramatically improve outcomes and reduce the side effects of each single modality treatment when therapeutic effects add up while side effects are distributed. In this context, nanoscale drug delivery agents have been developed and exploited to enhance the release of drugs in the treatment of several diseases, showing potential benefits in terms of pharmaceutical flexibility, selectivity, dose reduction and minimization of adverse effects.
View Article and Find Full Text PDFCorrigendum to "Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study" [The Journal of Prevention of Alzheimer's Disease 2024;11(3):567-581].
J Prev Alzheimers Dis
February 2025
AgenT, 4 rue Pierre Fontaine, 91000 Evry-Courcouronnes, France. Electronic address:
Distinct clinical outcomes based on multiple serum cytokine and chemokine profiles rather than autoantibody profiles and ultrasound findings in rheumatoid arthritis: a prospective ultrasound cohort study.
RMD Open
January 2025
Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Objectives: To evaluate the potential of clinical factors, ultrasound findings, serum autoantibodies, and serum cytokine and chemokine profiles as predictors of clinical outcomes in rheumatoid arthritis (RA).
Patients And Methods: We included 200 patients with RA treated with biological and targeted synthetic disease-modifying antirheumatic drugs in a prospective multicentre ultrasound cohort study. Their serum levels of multiple cytokines and chemokines, rheumatoid factors, and serum autoantibodies (anti-cyclic citrullinated peptide-2 (anti-CCP2) and anti-carbamylated protein antibodies) were measured at baseline, 3 months and 12 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!